Selected Therapeutic Areas

Responding to patients‘ needs.

CHEPLAPHARM offers a diversified product portfolio. Please find below a number of prescription drugs of selected therapeutic areas.


INSOMNIA

Insomnia is one of the most common sleep disorders characterized by difficulty falling and/or staying asleep with reduced quality, duration and restfulness of sleep. »

ROHYPNOL®

The worldwide marketed and well-established medicinal product ROHYPNOL® with its active ingredient Flunitrazepam belongs to the group of benzodiazepines. Benzodiazepines are centrally depressant psychotropic drugs with anxiolytic, anticonvulsant, sedative and sleep-inducing properties.

ROHYPNOL® is available as film-coated tablet containing 1 mg Flunitrazepam and indicated in short-term treatment of insomnia. It is subject to medicinal prescription (mostly via special narcotic prescription). 

ANTIDOTE

For therapeutic purposes, antidotes are generally used in cases of poisoning, medication overdose or exposure to industrial or other toxicological agents to minimize or compensate the mostly life-threatening reactions. »

ANEXATE®

The active ingredient of ANEXATE® is Flumazenil. As benzodiazepine antagonist, ANEXATE® acts as an antidote to drugs of the benzodiazepine class and is used in clinical settings for reversal of benzodiazepine sedation/ overdose.

OVERWEIGHT and OBESITY

Overweight and obesity are defined as abnormal or excessive fat accumulation caused by an imbalance between consumed and expended calories with a general impact on health condition. »

XENICAL®

XENICAL®, with its active substance orlistat, is a well-established medicinal product for the pharmacological treatment of overweight and obesity. It acts by the peripherally inhibition of gastrointestinal lipases. As a result the inactivated enzymes are unable to hydrolyze dietary triglycerides and, thus, the undigested triglycerides are not absorbed. Xenical® is indicated for treatment of obese or overweight patients (also for long-term obesity treatment) with associated co-morbidities, in conjunction with a mildly hypocaloric diet. Due to many years of clinical experience, the product has an established position in obesity treatment with positive benefit-risk profile and is first line therapy in addition to lifestyle interventions according to several national clinical practice guidelines. 

CARDIOVASCULAR DISEASES

Cardiovascular diseases summarize disorders affecting the heart and blood vessels including hypertension, coronary heart disease, congestive heart failure as well as cerebrovascular diseases.»

DILATREND® / CO-DILATREND® and ALDACTONE® / ALDACTONE® - SALTUCIN® FORTE

DILATREND® contains the active substance carvedilol, which is a third generation, multiple action adrenergic receptor blocker with ß1-, ß1- and ß2-adrenergic receptor blockade properties and additional anti-inflammatory and anti-oxidative characteristics. CO-DILATREND® further contains hydrochlorothiazide, that acts as diuretic by inhibition of the renal reabsorption of sodium and chloride. The active substance carvedilol is listed in the WHO list of essential medicines in the sections of antihypertensive medicines, medicines used in heart failure, antianginal medicines and antiarrhythmic medicines as well. According to many major clinical practice guidelines (e.g. United States, Europe, Australia), ß-blockers like carvedilol are first line therapy for the management of stable angina pectoris, additionally indicated as adjunctive therapy for the treatment of congestive heart failure and essential hypertension. 


ALDACTONE® contains as active substance spironolactone, which belongs to the pharmaceutical class of potassium-sparing diuretics. ALDACTONE® acts predominantly as a competitive antagonist of aldosterone leading to reduction of sodium reabsorption and potassium excretion by blocking the sodium-potassium exchange in the late distal tubules and collecting ducts of the kidney. The combination product of ALDACTONE® - SALTUCIN® FORTE further contains the substance thiazide butizide. Butizide inhibits sodium reabsorption in the early renal distal tubules and, thus, increasing the diuretic effect of spironolactone. The active substance spironolactone is listed in the WHO list of essential medicines in the sections of medicines used in heart failure and diuretics as well. With regard to the mode of action, ALDACTONE® is indicated in the treatment of primary and secondary hyperaldosteronism as well as edema due to hepatic cirrhosis, heart insufficiency or nephrotic syndrome, and respiratory insufficiency with chronic cor pulmonale. Furthermore, spironolactone is effective as add-on therapy in hypertension. 

LEUKEMIA

Leukemia is a type of cancer affecting the hematopoietic system and is caused by autonomic proliferation of abnormal white blood cells (leukocytes) and their accumulation in the bone marrow. »

VESANOID®

VESANOID® contains as active ingredient Tretinoin, a natural derivative of vitamin A. According to international clinical guidelines, VESANOID® represents an obligate part in the treatment of Acute Promeylocytic Leukemia (APL). The introduction of Tretinoin (VESANOID®) in APL treatment has transformed this leukemia type from very fatal to highly curable. Therefore, the active ingredient Tretinoin was included in the WHO (World Health Organization) list of essential medicines and exhibits in Europe unique selling proposition.

HEPATOBILIARY DISORDERS

Important disorders belonging to the hepatobiliary system pose Cholelithiasis and Primary Biliary Cirrhosis (PBC). Cholelithiasis involves the presence of gallstones, which are concretions of bile components that form in the biliary tract and may often be associated with Acute Cholecystitis. »

DEURSIL® / DE-URSIL® / URSOLVAN®

The medicinal products DEURSIL® / DE-URSIL® / URSOLVAN® possess as common active ingredient Ursodeoxycholic acid (UDCA), a natural bile acid occurring only to a minor degree in human being. The products are used for treatment of several hepatic and biliary disorders, e.g. cholesterol gallstones. According to e.g. European clinical guidelines, the active substance UDCA is recommended as first line treatment of Primary Biliary Cirrhosis (PBC).

ALCOHOL WITHDRAWAL

Alcohol is the most widely used and abused drug in the world, and alcohol use disorders lead to tremendous economic consequences for healthcare systems.  »

DISTRANEURIN® / HEMINEVRIN®

The active substance of the medicinal product is Clomethiazole, a short-acting hypnotic with sedative and anticonvulsant properties. According to several European guidelines, besides benzodiazepines, Clomethiazole is recommended as frontline-treatment concerning the therapy of acute alcohol withdrawal syndromes and delirium tremens. Additionally, DISTRANEURIN® / HEMINEVRIN® is also indicated in the management of restlessness and agitation in the elderly for clinical settings as well as in the treatment of severe insomnia if other therapies are not applicable. The product exhibits with its active substance Clomethiazole unique selling proposition on a global level.

INDURATIO PENIS PLASTICA

Induratio penis plastica (IPP, also called Peyronie’s disease) is a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis affecting an estimated 5% of men. »

POTABA-GLENWOOD®

The medicinal product POTABA-GLENWOOD® with its active substance Potassium 4-aminobenzoate is indicated in the treatment of Peyronie´s disease (Induratio penis plastic, IPP). According to Clinical Guideline on Penile Curvature of European Association of Urology, Potassium 4-aminobenzoate shows the best evidence-based efficacy of oral available medications in the treatment of IPP. POTABA-GLENWOOD® with its active substance Potassium 4-aminobenzoate exhibits worldwide unique selling proposition for the registered indication of IPP.